Nutraceuticals primary packaging
Other healthcare products
Our customized solutions around syringes
Our specific development services
Diagnostic and Life Sciences
Other medical products
SGH Healthcaring becomes SGH Medical Pharma and confirms its turnover target of €100 million by 2026.
The group is successfully pursuing its transformation plan to become a European leader in medical devices and drug administration, and a genuine partner contributing to its customers’ success in the pharmaceutical, life sciences and diagnostic sectors.
Saint-Marcellin (France), 20 October 2022 – SGH Healthcaring, a preferred partner of the pharmaceutical and diagnostic industries, with the ambition to become a leading European plastics manufacturer for the medical devices sector, sets out its four-year ambition and reveals its new brand identity: SGH Healthcaring is now SGH Medical Pharma.
A new identity to reflect the group’s transformation
By becoming SGH Medical Pharma, the group is affirming its identity, which is now firmly focused on the life sciences, diagnostic and pharmaceutical industries, and consolidating its reputation in its priority markets.
“Our strapline Inject your success clearly translates our positioning: contributing to our customers’ success. In a global context characterised by increasingly stringent supply and regulatory constraints, clients are glad to be able to rely on a leading, robust, agile key partner, capable of offering them tangible solutions to support their development”, says Olivier Derouard, Sales and Marketing Director.
As well as supplying drug administration systems (such as syringes, measuring cups, pill dispensers, Unicadose® and nasal aspirators), the group has significantly expanded its provision of bespoke solutions. From engineering to the regulatory environment and the development of custom machines, SGH Medical Pharma has invested and recruited to bolster its capacity for designing and manufacturing both bespoke devices and high added-value consumables.
A fast-growing group, despite the current economic situation
In four years, SGH Medical Pharma has consolidated its positions on the drug administration systems market thanks to the merger of Stiplastics (Isère), Rovipharm (Ain) and Eskiss (Allier) into a single entity. The group has also accelerated its move towards bespoke developments as a result of its ambitious transformation plan, which is targeting turnover of €50 million this year, i.e. almost 35% growth in three years, and €100 million in 2026, with over 60% generated abroad. With a presence in 50 countries, SGH Medical Pharma has strengthened its business in Germany in 2022 with the opening of an office in Frankfurt, as well as in the United States, where it already generates revenue of more than €1 million.
The mid-sized company, which now has 250 employees, has expanded its workforce (+20% compared with 2021), particularly in R&D, automation and sales. It is now planning to recruit more staff in production and support roles. SGH Medical Pharma has also consolidated its sales and marketing teams in Lyon, where they will shortly be joined by its support functions. The new site is centrally located between the group’s factories and anchors it in the heart of the rich health ecosystem of the capital of the Gauls.
Leading groups – such as Novartis, Haleon and Sanofi – have already put their faith in the group and in recent years, it has developed strategic partnerships with key actors in the diagnostics and life sciences sectors, such as bioMérieux or Agilent Technologies.
Factories 4.0 and 100% French production capacity
For the latter, a market leader in life sciences, diagnostics and applied chemistry, the partnership involves the annual production of 200 million pipette tips. SGH Medical Pharma is able to produce these volumes as a result of investing almost 10% of its turnover every year in optimising its production capacity, all of which is located in France.
As well as its know-how in plastic injection, for which it has earned a series of key certifications (ISO 13485, ISO 15378 and ISO 14001), SGH Medical Pharma’s strength also lies in its expertise in automation, which it has increased significantly in the last few years. At its Rovipharm site, which has recently begun manufacturing consumables for the fast-growing in vitro diagnosis market, the latest ISO 8 – ISO 7 – DNA/RNA-free cleanroom has production lines that require no human intervention. It houses five presses and 30 robots, with 100% of the components manufactured in it checked automatically. This move to factory 4.0 is only the first step and the group’s aim is to build on this success by transforming all of its facilities over the coming years.
“Our group has undergone a genuine transformation in recent years. Its new name, SGH Medical Pharma, will strengthen our positioning as a partner of choice for our customers in the health and medical sectors. It also unites our employees around a refreshed identity that is accompanied by an ambitious and proactive corporate social responsibility (CSR) policy. Despite the challenges of the current and future economic situation, we are confirming our ambition of becoming a European leader in medical devices and drug administration by supplying our customers “on time, in full”, all over the world,” concludes Jérôme Empereur, CEO of SGH Medical Pharma.
SGH Medical Pharma will be at CPHI – Stand 30B71, InnoPack area – from 1 to 3 November, Messe Frankfurt, Frankfurt, Germany.
About SGH Medical Pharma
SGH Medical Pharma is a rapidly growing group. Its aim is to become a leading European plastics manufacturer in medical devices, in vitro diagnosis and drug administration, as well as a key partner to the pharmaceutical, life sciences and diagnostic industries.
It has three manufacturing sites in France: Stiplastics (Isère), Rovipharm (Ain) and Eskiss (Allier), as well as an office in Lyon.
SGH Medical Pharma manufactures a comprehensive range of devices at several facilities certified to ISO 13485, including cleanrooms, and has complementary expertise in marketing, R&D, quality and industrial production for innovative products and medical subcontracting.